Peptide ELISA: Limit dilution 1: 128000. Western blot: 0.3-1 μg/mL. Approx 70 kDa band observed in human prostate lysates(calculated MW of 75.0 kDa according to NP_113605.2). Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Konzentration
0.5 mg/mL
Buffer
Tris saline, 0.02 % sodium azide, pH 7.3 with 0.5 % bovine serum albumin
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handhabung
Avoid repeated freezing and thawing.
Lagerung
4 °C/-20 °C
Informationen zur Lagerung
Store at 2 - 8 °C for up to one month or (in aliquots) at -20 °C.
MARK4 contains an N terminal serine/threonine kinase domain, a central ubiquitin associated domain, and a C terminal KA1 associated kinase domain. RT PCR analysis detects upregulated expression of the gene for MARK4 in nearly all clinical hepatocellular carcinoma cells. Northern blot analysis reveals ubiquitous expression of a 3.6kb transcript, with highest expression in testis. Immunofluorescence microscopy demonstrates homogeneous cytoplasmic expression. Colony forming assays show that MARK4 antisense reduces the growth of SNU475 cells. It has been suggested that MARK4 provides a growth advantage to cells.Synonyms: MAP microtubule affinity-regulating kinase 4, MARKL1